Clopidogrel Preferred to Reduce Heart Disease Risk in Patients With HIV
Researchers sought to determine whether clopidogrel would be preferred over aspirin to reduce cardiovascular risk in patients with HIV.
Diagnosis & Disease Information
Venous Thromboembolism or Major Bleeding Seen Frequently in Patients With Glioblastoma
Researchers sought to determine the rates of VTE and major bleeding in patients with glioblastoma.
Emicizumab May Improve Outcomes for Acquired Hemophilia A
Researchers sought to determine whether emicizumab would help improve outcomes for patients with acquired hemophilia A.
Phase 3 Results Confirm Emicizumab Is Safe for Hemophilia A
Researchers sought to confirm whether emicizumab is safe for treating patients with hemophilia A with factor VIII inhibitors.
Recombinant von Willebrand Factor Prophylaxis Effective at Preventing Bleeding in Patients With von Willebrand Disease
Researchers sought to determine whether recombinant VWF would be effective in reducing spontaneous bleeding for patients with severe VWD previously treated in an on-demand manner.
Association of COVID-19 With Venous Thromboembolism Events in Hospitalized Patients
Researcher sought to determine the risk of developing VTE in patients with and without COVID-19 who were hospitalized.
CDKN2A Deletion Predicts Risk of Venous Thromboembolism in Patients With Glioblastoma
Researchers sought to determine whether CDKN2A deletion could predict a higher risk of VTE in patients with glioblastoma.
Monoclonal Antibody Marstacimab Appears to Be Safe and Effective in Patients With Severe Hemophilia
Researchers sought to determine whether marstacimab would be effective in treating patients with severe hemophilia.
Analysis of the NEOCLOT Protocol for Patients With Catheter-Related Venous Thrombosis
Researchers evaluated the NEOCLOT protocol for management of catheter-related venous thrombosis in neonates in the Netherlands.
Gene Therapy Reduces Bleed Rates Among Patients With Hemophilia A
Researchers sought to determine whether valoctocogene roxaparvovec would reduce the risk of bleeding and rate of factor VIII infusion in patients with hemophilia A.
- Loading...
Loading...
Next post in Bleeding Disorders
Loading... 
Loading...